Sibutramine safety review

January 2002
WHO Drug Information;2002, Vol. 16 Issue 1, p26
Academic Journal
Reports on action taken by regulatory agencies of various countries regarding the prescription drug sibutramine. Approval of the drug in Canada in December 2000 to treat obesity; Italian authorities' temporary suspension of market authorization of all drugs containing sibutramine in March 2002; Announcement by French, German and English authorities that they are conducting reviews of the drug.


Related Articles

  • A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic patients Treated With Metformin. McNulty, Steven J.; Ur, Ehud; Williams, Gareth // Diabetes Care;Jan2003, Vol. 26 Issue 1, p125 

    OBJECTIVE To evaluate the effects of sibutramine (15 and 20 mg/day) on weight, metabolic control, and blood pressure in metformin-treated obese subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS — A 12-month randomized prospective placebo-controlled double-blind study was...

  • Cardiovascular Effects of Pharmacologic Treatments for Obesity. Aronne, Louis J. // Nutrition in Clinical Care;Jan/Feb98 Supplement 1, Vol. 1 Issue 1, p51 

    Examines the cardiovascular effects of pharmacologic treatment for obesity in the United States. Complications of obesity; Development of sibutramine as an antidepressant; Association between sibutramine and heart disease and hypertension.

  • Continuous and intermittent sibutramine were equally effective at 44 weeks for reducing weight in obese persons. Cheskin, Lawrence J. // ACP Journal Club;Mar/Apr2002, Vol. 136 Issue 2, p49 

    Presents information on a study which examined the effectiveness of sibutramine for reducing weight in obese patients. Methodology of the study; Results; Comments on the study.

  • Pharmacological Treatment of Obesity: Current Standards and Future Perspectives. Romijn, J. A.; Smit, J. W. A.; Pereira, A. M.; Corssmit, E. P. M.; Pijl, H. // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Feb2006, Vol. 6 Issue 1, p119 

    The long-term effects on weight have only been studied for orlistat and sibutramine. The net effects of these drugs vary between 2-5% loss of weight after 1-2 years of treatment. However, the effects of orlistat and sibutramine on morbidity and mortality have not been studied extensively. In the...

  • FROM THE ANALYST'S COUCH: Obesity market overview. Farrigan, Christine; Pang, Kevin // Nature Reviews Drug Discovery;Apr2002, Vol. 1 Issue 4, p257 

    Presents an overview of available pharmacological therapies for obesity. Sibutramine; Axokine; Bupropion; Recombinant human leptin; Topiramate; Forecast of sales of antiobesity agents by 2010.

  • A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity. Fanghänel, G; Cortinas, L; Sánchez-Reyes, L; Berber, A // International Journal of Obesity & Related Metabolic Disorders;Feb2000, Vol. 24 Issue 2, p144 

    OBJECTIVE: To evaluate the safety and efficacy of Sibutramine 10 mg per os, once a day in obese patients over a period of 6 months. DESIGN: A monocenter, double-blind, placebo-controlled, parallel, prospective clinical trial. SUBJECTS: 109 male and female obese patients (BMI >30 kg/m²) from...

  • Sibutramine/zolpidem interaction.  // Reactions Weekly;Feb2014, Vol. 1488 Issue 1, p31 

    The article presents a case study of a 61-year old woman who suffered from two psychotic episodes during treatment with sibutramine for obesity.

  • BATTLING THE BULGE. Beyzarov, Elena Portyansky // Drug Topics;8/21/2000, Vol. 144 Issue 16, p51 

    Deals with the drugs and herbal medicines to fight obesity. Factors causing obesity and its health implications; Evaluation of earlier pharmacologic treatments for obesity; Mechanism of action and side effects of Meridia and Xenical drugs; Herbal ingredients in weight loss supplements. INSET:...

  • New Trends in Medicinal Chemistry Approaches to Antiobesity Therapy. Jinhwa Lee; Kwang-Seop Song; Jahyo Kang; Suk Ho Lee; Junwon Lee // Current Topics in Medicinal Chemistry;Apr2009, Vol. 9 Issue 6, p564 

    The prevalences of overweightedness and obesity are increasing globally at frightening rates, driven by social and economic changes. Furthermore, obesity is associated with the pathogeneses of major diseases, particularly diabetes and cardiovascular diseases. However, no satisfactorily safe,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics